Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 11/20 | 0.54 |
| ▸ | CA9 | Q16790 | 11/20 | 0.54 |
| ▸ | CA2 | P00918 | 9/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 8/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7559546 | 0.81 | CA12 (0.56) | CA12CA9CA2MAPTNPSR1 | |
| SCHEMBL5757808 | 0.81 | MAPT (0.63) | CA12CA9CA2MAPTNPSR1 | |
| Ethylene SCHEMBL8378460 | 0.80 | CA12 (0.58) | CA12CA9CA2MAPTNPSR1 | |
| SCHEMBL7370172 | 0.80 | CA12 (0.58) | CA12CA9CA2MAPTNPSR1 | |
| SCHEMBL5758569 | 0.80 | GRIA3 (0.61) | GRIA3GRIA4 | |
| SCHEMBL7361750 | 0.77 | CA12 (0.71) | CA12CA9CA2MAPTNPSR1 | |
| SCHEMBL548486 | 0.72 | CA12 (1.00) | CA12CA9CA2CA1SMYD3 | |
| SCHEMBL10576406 | 0.70 | CA12 (0.74) | CA12CA9CA2MAPTNPSR1 | |
| SCHEMBL3282985 | 0.70 | CA12 (0.74) | CA12CA9CA2CA1SMYD3 | |
| SCHEMBL7804507 | 0.69 | NOS2 (0.63) | CA12CA9CA2MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020055498-A1 | Benzofurazan compounds for enhancing glutamatergic synaptic responses | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055498-A1 | Benzofurazan compounds for enhancing glutamatergic synaptic responses | GRIN1, GABRE, GABRG1 | CA12 4210/4885CA9 4871/4885CA2 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.